Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction–negative samples obtained after treatment of chronic hepatitis C by Morishima, Chihiro et al.
Interpretation of Positive Transcription-Mediated
Amplification Test Results from Polymerase Chain
Reaction–Negative Samples Obtained After
Treatment of Chronic Hepatitis C
Chihiro Morishima,1 Timothy R. Morgan,2 James E. Everhart,3 Elizabeth C. Wright,4 Minjun C. Apodaca,1
David R. Gretch,1 Mitchell L. Shiffman,5 Gregory T. Everson,6 Karen L. Lindsay,7 William M. Lee,8 Anna S. F. Lok,9
Jules L. Dienstag,10 Marc G. Ghany,11 Teresa M. Curto,12 and the HALT-C Trial Group
The Siemens VERSANT® transcription-mediated amplification (TMA) assay is extremely sensitive
for the detection of hepatitis C virus (HCV) RNA in serum. Eleven of 180 subjects in the Hepatitis C
Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial who achieved polymerase chain
reaction (PCR)-defined sustained virological response (SVR) at week 72 also had TMA-positive
results fromthesameblooddraw; sixwerepositiveonrepeat testing.Wereport the follow-uponthese
11 patients, and the reproducibility of TMA test results from PCR-negative samples in relationship to
antiviral treatment outcome. Peginterferon and ribavirin treatment was initiated in 1145 prior inter-
feronnonresponderswithadvancedhepaticfibrosis.Treatmentwascontinuedfor48weeks ifpatients
hadundetectableHCVRNAbyPCRat treatmentweek20.Frozenserumsamples fromweeks12,20,
24,48,and72weresubsequently testedbyTMA.Nineof the11patients returnedfor testing(median,
30 months after the week 72 visit), and all had undetectable HCV RNA by TMA and PCR. Among
759 PCR-negative samples obtained during treatment that were tested twice by TMA, 17% overall
exhibited consistently positive results, and 21% exhibited inconsistently positive results. SVR was
more likely if TMA was consistently negative than if consistently or inconsistently positive. With
continued treatment, patients with inconsistently positive TMA results were more likely to become
TMA-negative than TMA-positive (P < 0.0001). Conclusion: In PCR-negative samples, positive
TMA results may indicate the presence of low levels of HCV RNA. However, because patients with
positiveTMAresultsmayachieveSVR,managementdecisionsduringtherapyshouldnotbebasedon
a single positive TMA test result. (HEPATOLOGY 2008;48:1412-1419.)
Abbreviations: BT/R, breakthrough/relapse; HALT-C, hepatitis antiviral long-term treatment against cirrhosis; HCV, hepatitis C virus; LLOD, lower limit of detection;
PCR, polymerase chain reaction; SVR, sustained virological response; TMA, transcription-mediated amplification.
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The success of antiviral therapy for chronic hepati-tis C is currently assessed by hepatitis C virus(HCV) RNA testing at least 24 weeks after com-
pletion of therapy.1 Patients with undetectable virus at
this juncture are considered to have achieved a sustained
virological response (SVR), which has been associated
with durable eradication of infection.2-5
In clinical trials, investigators have relied on qualitative
HCV RNA assays [using polymerase chain reaction (PCR)]
with lower limits of detection of approximately 50 to 100
IU/mL to establish undetectable HCV RNA levels during
and after treatment.1,6 Recently, the Siemens VERSANT
HCV RNA Qualitative Assay, based on transcription-medi-
ated amplification (TMA) technology, was approved by the
US Food and Drug Administration for detection of HCV
RNA in serum as evidence of active infection. The TMA
assay has a lower limit of sensitivity of 5 to 10 IU/mL.7-10 We
recently described the performance of TMA for predicting
SVR during the lead-in phase of the Hepatitis C Antiviral
Long-Term Treatment against Cirrhosis (HALT-C) Trial,
in which 1145 patients received combination pegylated in-
terferon and ribavirin. Several studies, including our own,
have demonstrated that positive TMA results at the end of
treatment (week 48), despite negative results by PCR, iden-
tify subjects who subsequently relapse after cessation of treat-
ment.10-14
Through extensive testing of our cohort, we have identi-
fied HALT-C Trial subjects with serum samples that were
PCR-negative but TMA-positive during and after peginter-
feron and ribavirin treatment. The clinical implications of
such results are uncertain, but potentially important, because
clinicians are likely to base decisions regarding response to
treatment on a single qualitative result, using the most sen-
sitive assay available. In this analysis, we explore the clinical
meaning of a positive TMA test in subjects with a negative
PCR result for HCV RNA during or after peginterferon and
ribavirin treatment.
Patients and Methods
Patients and Samples. The overall design of the
HALT-C Trial has been described in detail.15 Briefly,
1145 subjects with bridging fibrosis or cirrhosis who were
nonresponders to prior treatment with interferon (with or
without ribavirin) were retreated with peginterferon
alfa-2a 180 g/week and 1000 to 1200 mg/day of ribavi-
rin during the lead-in phase of the trial. Subjects with
undetectable HCV RNA using the Roche COBAS® Am-
plicor HCV Test, v. 2.0 assay (or PCR assay) at treatment
week 20 received a total of 48 weeks of treatment with
follow-up monitoring through week 72. SVR was defined
as undetectable HCV RNA by PCR at week 72. Subjects
with detectable HCV RNA at week 20 by PCR were
deemed to be nonresponders to peginterferon/ribavirin,
and treatment was discontinued at week 24. Clinical and
other laboratory data were collected from all subjects ac-
cording to standard procedures.15 Serum samples ob-
tained during the study were tested for HCV RNA at
weeks 12, 20, 24, 48, 60, and 72. Frozen (80°C) serum
samples were subsequently tested by TMA as part of this
study, including week 72 samples from all patients who
had achieved SVR (defined by PCR). Patients who had
achieved SVR but had positive week 72 samples by TMA
were asked to return for repeat virological testing and
clinical evaluation. The Institutional Review Boards of all
participating institutions approved the study protocols,
and written informed consent was obtained from all study
subjects.
Virological Testing. Serum samples obtained from all
subjects enrolled in the HALT-C Trial were frozen at each
clinical site then shipped on dry ice and tested in real time
at the University of Washington Virology Laboratory
with both the quantitative Roche COBAS® Amplicor
HCV Monitor Test, v. 2.0 assay [lower limit of detection
(LLOD) 600 IU/mL] and, if negative, by the Roche CO-
BAS® Amplicor HCV Test, v. 2.0 assay (or PCR assay,
LLOD 100 IU/mL) as previously described.16,17 HCV
genotypes were determined with the INNO-LiPA HCV
II kit (Siemens Medical Solutions Diagnostics, Tarry-
town, NY).
The Siemens VERSANT® HCV RNA Qualitative As-
say (or TMA assay) (Tarrytown, NY) was used to test
thawed serum samples, according to the manufacturer’s
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instructions, except that five additional negative controls
(HCV-seronegative serum samples) and an additional
low-positive (sensitivity) control were used in each run of
88 patient samples. All stages of testing by this assay—
sample preparation, target amplification, and amplicon
detection—were performed within a single tube as de-
scribed previously.10 Briefly, the 5 untranslated region of
the HCV genome was amplified under isothermal condi-
tions. Chemiluminescence of two differentially modified
acridinium ester molecules attached to different probes
allowed for the simultaneous detection of internal control
and HCV RNA targets, as measured in relative light units.
Each test result was considered valid if the internal control
result was reactive for that sample. In our laboratory,
HCV RNA is detected 100% of the time in serum by
PCR at 100 IU/mL and TMA at 5 IU/mL.10
In this analysis, a large number of serum samples were
tested twice by TMA in separate batches. The bulk of the
TMA reproducibility data was obtained using PCR-negative
serum samples because we had previously established that
essentially all PCR-positive samples are also positive by
TMA.10 If PCR was negative and TMA positive, the results
were considered “discrepant.” If results of duplicate TMA
tests from a single blood draw were the same (in other words,
both results were negative or both results were positive), they
were considered to be “concordant.” If one TMA result was
positive and the repeat TMA result was negative or vice versa,
the results were considered to be “discordant.”
Statistical Analyses. Chi-square tests were used to
compare the percentage of positive or discordant tests
among groups of patients or at different times. Analyses of
results from multiple visits per patient were performed
with the Cochran-Mantel-Haenstzel chi-square, stratified
by visit number. Data were analyzed with SAS (Statistical
Analysis Software, Cary, NC) version 9.1.
Results
Discrepant Results Obtained by PCR and TMA
Testing After Completion of Antiviral Therapy. A to-
tal of 245 patients who had undetectable HCV RNA by
PCR at the week 20 time point were also tested for HCV
RNA at week 72 using the Roche COBAS® Amplicor
test. One hundred eighty (70%) of these patients had
undetectable HCV RNA using this assay and were
deemed sustained virological responders. The TMA assay
was positive on previously unthawed week 72 aliquots
from 11 of these 180 patients (6.1%) (Table 1). This
discrepancy could reflect the difference between the de-
tection limits of the two assays (5 IU/mL for the TMA
versus 100 IU/mL for the PCR test).10 Alternatively, the
discrepancy could have been caused by false-positive test-
ing for HCV RNA by TMA or false-negative testing by
PCR. The 11 TMA-positive results were derived from
blood samples drawn and processed at six HALT-C clin-
ical sites and were obtained from four separate runs of the
TMA assay. Results from 9 of 11 samples produced ro-
bust signals (relative light units) relative to the positive
threshold. All 11 patients had responded promptly to
combination therapy with at least a 2 log10 decrease of
HCV RNA levels by week 12 (early virological response),
with 5 of these 11 also TMA-negative at week 12. All 11
patients also had remained TMA-negative and PCR-neg-
ative for HCV RNA from week 20 through week 48, with
the exception of two subjects who had single TMA-posi-
tive results during therapy (one at week 20 and another at




























1 6 3a 1.34 64 33 –  1/3 23 – – 2/2 34
2 3 1a 1.71 75 29 –  1/3 24 – – 2/2 69
3 3 1a 0.48 96 52 –  1/4 46 – – 2/2 38
4 6 1b 2.09 245 50 –  1/4 46 – – 2/2 33
5 3 1b 0.79 98 50 –  1/4 47 – – 2/2 31
6 3 1b 6.86 80 23 –  2/4 23 – – 2/2 21
7 3 2 0.61 215 57 –  2/4 37 – – 2/2 33
8 2 3a 1.69 39 35 –  2/4 LT F/U LT F/U LT F/U LT F/U LT F/U
9 2 1a/1b 11.4 50 32 /–†  3/3 20 – – 2/2 32
10 5 1a 1.06 36 25 –  2/2 30 – – 2/2 23
11 2 1a 8.09 78 41 –  2/2 LT F/U LT F/U LT F/U LT F/U LT F/U
*Months of follow-up after week 72 (W72) visit.
†This subject had detectable serum HCV RNA by qualitative PCR (Amplicor) but not by quantitative PCR (Monitor) at his W72 visit. However, a repeat blood draw
was negative by qualitative PCR shortly thereafter and he was considered an SVR. Samples from weeks 24, 36, 48, and 60 were also PCR-negative.
GT, HCV genotype; ALT, alanine aminotransferase (IU/mL); W72, week 72; PCR-, polymerase chain reaction-negative, defined as 100 IU/mL; TMA-, transcription-
mediated amplification-negative, defined as 5 IU/mL; LT F/U, lost to follow-up.
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week 48). Samples obtained from all 11 subjects at week
60 (off therapy) also were negative by TMA and PCR.
Initial HCV RNA levels for the 11 patients ranged from
480,000 IU/mL to 11,400,000 IU/mL (median
1,690,000 IU/mL), and the patients were infected with
various HCV genotypes, including 1a, 1b, 2, and 3a.
Additional aliquots of serum obtained at the week 72
time point from the 11 subjects were retested by the TMA
assay within 3 months of the first TMA result (Table 1).
All 11 subjects had sufficient serum for one repeat TMA
test, whereas 9 of 11 individuals had sufficient serum
available for three to four replicates to be performed. Six
patients had a positive TMA result on repeat testing, and
five had negative (discordant) results. The two samples
with low relative light units initially were strongly positive
on a second TMA test. Nine of these 11 patients had
repeat clinical examination and HCV RNA testing by our
laboratory at a median 30 months (range, 20-47 months)
after the week 72 visit. On this return visit, all nine pa-
tients had HCV RNA undetectable by TMA testing of
two separate aliquots of serum as well as by PCR (Table
1). One patient had an elevated alanine aminotransferase
(patient 2, alanine aminotransferase  69). Seven of these
patients also had had negative repeat HCV RNA testing
(usually by PCR) in local laboratories after week 72, and
five of the seven had had negative tests on multiple occa-
sions.
Reproducibility of TMA Results During Treatment.
The finding that 11 patients with well-documented SVR
at week 72 had serum that was positive by TMA, and that
6 of these 11 patients had positive results on repeat TMA
testing led us to evaluate the reproducibility of the TMA
assay. Potentially, the week 72 discrepant and discordant
results could have been attributable to false-positive re-
sults in the initial TMA assay from laboratory or handling
error. Alternatively, these samples might have contained
extremely low levels of HCV RNA (5 IU/mL), resulting
in sampling variability with each test, as would be ex-
pected to occur near the limit of detection.
To evaluate the reproducibility of the TMA test, we
first selected 30 serum samples randomly from patients
with detectable HCV RNA by the Roche COBAS® Am-
plicor (PCR) test (LLOD, 100 IU/mL) but undetectable
by the quantitative Monitor® test (LLOD, 600 IU/mL)
for retesting with the TMA assay. All 30 samples had
detectable HCV RNA on the first and repeat testing in
separate runs by the TMA assay (data not shown). Thus,
the reproducibility of the TMA test was 100% for samples
containing HCV RNA levels that were greater than ap-
proximately 100 IU/mL.
As a next step, we performed replicate TMA testing on
samples with HCV RNA-negative results by PCR (100
IU/mL) (Table 2). A total of 815 randomly selected PCR-
negative samples from various time points during therapy
were therefore tested with the TMA assay on two separate
aliquots on two separate occasions. Of these 815 samples,
274 had tested positive on initial TMA testing whereas
541 had tested negative.
To better understand the meaning of TMA test results
among subjects with HCV RNA-negative results by PCR,
we evaluated the virological outcome of these subjects
according to the results of their duplicate TMA tests. In
Table 2. TMA Reproducibility Results Among PCR-Negative Samples
TMA Results Week 12 Week 20 Week 24 Week 48 Total
N (%) N (%) N (%) N (%) N (%)
Among SVR
Negative/negative 110 (78.6%) 68 (84.0%) 62 (89.9%) 85 (95.5%) 325 (85.8%)
Discordant 9 (6.4%) 8 (9.9%) 5 (7.2%) 4 (4.5%) 26 (6.9%)
Positive/positive 21 (15.0%) 5 (6.2%) 2 (2.9%) 0 (0.0%) 28 (7.4%)
Total 140 (100%) 81 (100%) 69 (100%) 89 (100%) 379 (100%)
Among BT/R
Negative/negative 15 (21.4%) 37 (28.0%) 36 (36.4%) 60 (76.0%) 148 (39.0%)
Discordant 21 (30.0%) 41 (31.1%) 25 (25.3%) 10 (12.7%) 97 (25.5%)
Positive/positive 34 (48.6%) 54 (40.9%) 38 (38.4%) 9 (11.3%) 135 (35.5%)
Total 70 (100%) 132 (100%) 99 (100%) 79 (100%) 380 (100%)
% SVR According to TMA Reproducibility*
TMA Results Week 12 Week 20 Week 24 Week 48
Total% % % %
Negative/negative 88.0% 64.8% 63.3% 58.6% 68.7%
Discordant 30.0% 16.3% 16.7% 28.6% 21.1%
Positive/positive 38.2% 8.5% 5.0% 0.0% 17.2%
BT/R, breakthrough or relapse defined as reappearance of HCV RNA by PCR during or after completing peginterferon and ribavirin therapy.
*P  0.0001 at all time points and overall for comparison of three groups and SVR, both as categories and as trend (Cochran-Mantel-Haenstzel chi-squared,
stratified by time point).
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all of these analyses, we reasoned that if TMA-discordant
results were a consequence of laboratory or handling er-
ror, then they should not be associated with any particular
virological pattern or outcome. Conversely, if discordant
TMA results were attributable to low HCV RNA copy
numbers close to the limit of detection, then discordant
results might be expected to reflect a transition from HCV
RNA consistently detectable to HCV RNA consistently
undetectable by TMA as HCV infection cleared. Such a
transitional state would also be predicted to become less
common with longer duration of treatment and found
less frequently in patients who achieved a clinical SVR.
We performed three analyses based on the results of
this replicate TMA testing. For the first analysis, we eval-
uated the frequency of concordant or discordant TMA
results among subjects who achieved an SVR and those
who failed to achieve an SVR [in other words, break-
through/relapse (BT/R), Table 2]. Only patients with
known week 72 virological outcomes were included in the
analysis. Among samples from patients with SVR, the
overall rate of discordance (across treatment weeks 12, 20,
24, and 48) between the first and second TMA result was
6.9% (26/379) compared with 25.5% (97/380) among
patients without SVR (P  0.0001). For both groups, the
rate of TMA-discordant and TMA-positive/positive re-
sults declined from week 12 to week 48. Finally, at each
treatment week, TMA-discordant and TMA-positive/
positive results were more common among patients with
BT/R than among those with SVR (P  0.0001).
We also examined the data set in a second way, by
analyzing the ability of concordant and discordant TMA
results to predict SVR (Table 2, bottom). TMA-negative
samples that were negative on repeat testing were associ-
ated with a high rate of SVR (68.7% overall), with the
highest SVR rate observed when the TMA results were
negative early in treatment (for example, 88% at week
12). By contrast, samples that were repeatedly TMA-pos-
itive predicted a much lower rate of SVR (17.2% overall),
where the likelihood of SVR was lower if samples were
collected after a longer duration of therapy (range, 38.2%
SVR at week 12 to 0% SVR at week 48). Finally, if the
sample yielded discordant TMA results, the likelihood of
achieving SVR was similar to that of samples with repro-
ducibly TMA-positive results (21.1% overall).
For the third analysis, we tested the hypothesis that
TMA-discordant virological results reflected a very low
virus level or “phase” during therapy through which some
patients passed en route to becoming HCV RNA-unde-
tectable. To this end, we analyzed sequential virological
results among patients who had a TMA-discordant result
at week 12 with a subsequent week 20 result or had a
TMA-discordant result at week 20 with a subsequent
week 24 result (Fig. 1). For this analysis, a positive sample
was defined as one that was PCR-positive or TMA-posi-
tive (singly or in duplicate) and a negative sample was
defined as one that was TMA-negative (singly or in du-
plicate). We then determined whether a TMA-discordant
result was more likely to be followed in time (during
therapy) by a TMA-negative or positive result. The TMA-
discordant result was more likely to be followed by a
TMA-negative than positive result. Of 21 subjects with
discordant results at week 12, 19 became HCV RNA-
negative compared with two who became HCV RNA-
positive at week 20. Likewise, of 32 subjects with
discordant results at week 20, 24 became HCV RNA-
negative compared with eight who became HCV RNA-
positive at week 24 (P  0.0002 and P  0.0047,
respectively, testing whether the proportion of TMA-neg-
ative and TMA-positive samples after TMA discordance
differs from 50%). This pattern suggests that during
peginterferon treatment and at concentrations of HCV
RNA that are undetectable by PCR, the HCV RNA level
declined from TMA-positive to TMA-discordant (very
low levels) to TMA-undetectable.
Discussion
The absence of detectable serum HCV RNA by PCR 6
months after completing therapy is the definition for























Fig. 1. Longitudinal virological results after discordant or inconsistent
TMA results at week 12 or week 20 of treatment. Patients included in this
analysis were those who: (left panel) had HCV RNA–positive results at
baseline, had TMA-discordant () results at week 12, and subsequent
virological results available at weeks 20 or (right panel) had HCV
RNA-positive results at week 12, had TMA-discordant () results at week
20, and subsequent virological results available at week 24. Positive
samples () were defined as those that were PCR-positive or TMA-
positive (singly or in duplicate). Negative samples () were defined as
those that were TMA-negative (singly or in duplicate). TMA-discordant or
inconsistent results at weeks 12 or 20 were more likely to be followed by
TMA-negative than TMA-positive results (19 negative versus 2 positive,
P  0.0002 and 24 negative versus 8 positive, respectively, P 
0.0047).
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treatment success in hepatitis C patients receiving pegin-
terferon and ribavirin therapy.1 We and others have
shown that the TMA assay is highly sensitive for HCV
RNA detection7-10 and that HCV RNA can be detected
by TMA in samples that are HCV RNA-negative by stan-
dard PCR assays.10-14,18 With increased TMA sensitivity,
however, may come reduced specificity, and as TMA as-
says become increasingly available at clinical laboratories,
the meaning of a positive TMA test during and after treat-
ment should be understood before clinical decisions are
based on such a result. In the current study, we examined
the long-term virological outcome of subjects receiving 48
weeks of peginterferon and ribavirin with a positive TMA
result at week 72. We further investigated the reproduc-
ibility of TMA results among serum samples that were
negative by a qualitative PCR test (sensitivity, 100 IU/
mL).
The most notable finding was that HCV RNA detect-
able by TMA but undetectable by PCR did not necessar-
ily signify that a clinically meaningful serum level of virus
was present. This conclusion was supported most strik-
ingly by the observation of a true SVR in nine patients (as
defined by long-term follow-up) in whom PCR was neg-
ative but TMA was positive 24 weeks after completing 48
weeks of peginterferon and ribavirin therapy. Consistent
with their achieving an SVR, these patients had a prompt
drop in HCV RNA on therapy, were repeatedly PCR-
negative from week 20 through week 72, and had a sig-
nificant decline in alanine aminotransferase activity from
baseline to week 72. Most importantly, all nine remained
HCV RNA-negative by both PCR and TMA after week
72. Although other investigators, using less sensitive
methods for detecting HCV RNA, have described the
presence of low-level HCV in serum and liver after suc-
cessful peginterferon/ribavirin treatment,2,5,19 in these
nine patients, a positive TMA test did not signify a clini-
cally meaningful recrudescence of HCV infection.
Because the TMA results at week 72 were shown to be
consistently positive among several of the patients in the
setting of apparent true SVRs, we systematically retested a
large number of PCR-negative aliquots from patients who
did or did not achieve SVR using the TMA assay (Table
2). At all time points tested, PCR-negative samples with
consistently positive as well as inconsistently positive re-
sults by TMA were identified. It was notable that patients
with BT/R had much higher rates of TMA-positive/pos-
itive or TMA-discordant results than patients with SVR,
suggesting that a positive TMA result, even if discordant,
accurately detects HCV RNA and predicts a lower likeli-
hood of successful clearance with peginterferon and riba-
virin treatment. Finally, at week 12 of therapy, patients
with SVR had as high a proportion of consistently nega-
tive TMA results (78.6%) as did patients with BT/R at
the end of therapy (76.0%). These results are consistent
with the interpretation that the antiviral pressure of
peginterferon/ribavirin treatment is more successful at
eliminating circulating HCV RNA during therapy in
those who will eventually achieve SVR compared with
those who do not, and that such control may occur later
and is ultimately inadequate in those who do not achieve
SVR.
We have previously shown that, among patients with
negative PCR results while on antiviral therapy, virologi-
cal breakthrough or relapse was preceded by a positive
TMA result in most but not all subjects.10 Thus, for clin-
ical guidance, knowing the reproducibility of TMA and
the likelihood of SVR based on the TMA result is impor-
tant for patient management. Among PCR-negative sam-
ples in this study, 16% of all samples tested twice by TMA
exhibited inconsistent or discordant results. Over all time
points, consistently negative TMA results led to a 69%
likelihood of SVR, whereas consistently positive results
led to a 17% likelihood of SVR. When TMA results were
inconsistent on repeat testing, the overall likelihood of
SVR was 21%, only slightly greater than in patients with
consistent TMA-positive results. This observation sup-
ports the hypothesis that HCV RNA was present in the
samples that exhibited inconsistently TMA-positive re-
sults.
Successful antiviral treatment usually results in pro-
gressively lower levels of HCV RNA with longer duration
on therapy until the virus is no longer detectable. With a
highly sensitive qualitative test such as TMA, we hypoth-
esized that discordant or inconsistent results might follow
reproducibly positive results and precede reproducibly
negative results as viral levels declined. The patterns
shown in Fig. 1 are consistent with this hypothesis. Pa-
tients were much more likely to have the sequence of
TMA-positive followed by discordant followed by nega-
tive than they were to have the sequence of TMA-positive
followed by discordant followed by positive.
Although we cannot exclude the possibility that labo-
ratory or handling error could have contributed to some
of the discordant results reported here, the patterns of
TMA reproducibility observed in this study suggest that
the bulk of the discordant results reflect low levels of
HCV RNA in PCR-negative/TMA-discordant samples.
Such a conclusion is consistent with our previous descrip-
tion of samples containing less than 5 IU/mL (from a
defined HCV RNA standard) in which HCV RNA was
detected inconsistently by TMA.10 Although laboratory
errors also could have contributed to the week 72 TMA-
positive results in the 11 patients with PCR-defined SVR,
all negative controls in those runs were negative, and no
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other aberrant results were noted. The HALT-C virology
laboratory has stringent procedures in place to minimize
the possibility of contamination including the use of sep-
arate “clean” and “product” areas combined with a desig-
nated work flow plan that prohibits moving from the
“product” to the “clean” area in a single day. Further-
more, these positive results were obtained on four separate
runs, and contamination from neighboring wells could
not have accounted for all of the results reported.
In clinical practice, serum samples are unlikely to be
tested repeatedly by a qualitative test for HCV RNA,
much less tested repeatedly by two qualitative tests as was
done in this study. The HALT-C Trial, however, pro-
vided a unique opportunity to demonstrate the reproduc-
ibility of the TMA qualitative test in a large number of
patients treated under a standardized protocol and whose
serum samples were tested at a dedicated, single-site, vi-
rology laboratory. In the absence of another HCV RNA
assay with 100% detection at 5 IU/mL, we cannot con-
clude definitively that unexpectedly and inconsistently
positive samples by TMA resulted from very low levels of
virus in the PCR-negative samples. However, we have
presented evidence that inconsistent detection of HCV
RNA by TMA was not random, as would have been ex-
pected with laboratory error. Rather, our data were most
consistent with the hypothesis that inconsistent detection
of HCV RNA in the TMA assay reflects the sampling
variability that occurs in the presence of very low levels of
the target molecule. Moreover, it suggests that patients
successfully treated for HCV infection could potentially
harbor extremely low levels of HCV RNA after treatment.
Highly sensitive assays such as TMA are being increas-
ingly used to monitor response to therapy. Thus, detailed
information on the limitations of these sensitive assays is
important for therapeutic management. Some sugges-
tions regarding the clinical use of TMA were discussed in
a prior manuscript.10 The TMA assay can detect the pres-
ence of HCV RNA among patients in whom a PCR assay
is negative. However, a single positive TMA test result
should be interpreted with caution, because, in our cohort
of patients, a single positive TMA test did not necessarily
signify nonresponse to treatment or failure to achieve
SVR. Our previous finding that 2 of 19 patients (11%)
with PCR-negative but TMA-positive results at the end of
therapy (week 48) still achieved SVR10 lends additional
weight to this warning. Whether positive TMA results
could potentially represent the detection of replication-
incompetent HCV RNA in these patients is unknown. It
is important to note that the added sensitivity of the TMA
assay has been shown to provide useful information in
other settings10-14; thus, we encourage additional studies
to be performed in other cohorts. Nevertheless, based on
our findings, we suggest that decisions regarding the clin-
ical management of patients during hepatitis C antiviral
therapy should be made differently if highly sensitive
qualitative tests are used (LLOD 5-10 IU/mL), rather
than less sensitive HCV RNA tests (LLOD 50-100 IU/
mL). Here, we have examined the reproducibility of
TMA among PCR-negative samples during and after
therapy. Based on these results, we would specifically dis-
courage the use of single TMA test results for treatment
discontinuation decisions, as is currently recommended
for PCR-based assays. Moreover, unexpected TMA-pos-
itive results may best be handled by careful clinical follow-
up.
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